Norxacin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norxacin

Property Description
Active Ingredient Norfloxacin
Form Tablet, Ophthalmic solution, Otic solution
Pharmacological Class Fluoroquinolone Antibiotic (Second Generation)
General Purpose Treatment of susceptible bacterial infections
Origin Synthetic Compound

What Type of Medicine is Norxacin?

Norxacin is a prescription-only pharmaceutical preparation classified as a synthetic antimicrobial agent, specifically a second-generation fluoroquinolone antibiotic. Its core active component is the substance Norfloxacin, which defines its therapeutic identity. The compound Norfloxacin is a synthetic derivative based on the quinolone chemical structure, making it distinct from naturally derived antibiotics. This medicine is an artificially created chemical agent designed for use against susceptible pathogens. As a single-active-ingredient product, Norxacin belongs to a class of antibiotics known for their ability to combat a broad-spectrum of susceptible bacterial pathogens.


Composition and Available Forms of Norxacin

Norxacin contains Norfloxacin as its sole active ingredient and is supplied in distinct pharmaceutical forms to suit the required route of administration. For managing systemic bacterial issues, the medicine is most commonly presented as tablets intended for oral use. For localized bacterial issues, particularly in sensitive areas, the preparation is also manufactured as sterile aqueous solutions for topical application, such as ophthalmic solutions for the eyes or otic solutions for the ears. Norfloxacin is characterized as an antibacterial medicine, serving a primary role in fighting bacteria and functioning as a medicine for combating bacterial infections.


What is the General Purpose of Norfloxacin?

The general purpose of Norxacin is to resolve infections caused by bacteria that are susceptible to its unique mechanism of action. This medicine achieves its therapeutic goal by exhibiting a bactericidal effect, meaning it actively kills the offending bacterial organisms. The medicine functions by interfering directly with the bacteria's essential ability to copy and repair its own DNA, effectively eliminating the pathogenic bacterial load and helping the body overcome the underlying disease state. This mechanism is applicable for infections where this class of antibiotic is the preferred treatment.

Regulatory References

  1. WHO AWaRe Classification

What side effects are possible with Norxacin?

Possible side effects and safety information: Norxacin

Norxacin, a fluoroquinolone antibiotic, carries specific safety warnings concerning potentially serious and permanent adverse effects.

Serious and Disabling Adverse Reactions

Regulatory authorities have issued warnings concerning several serious side effects. These include tendinopathy and tendon rupture (particularly the Achilles tendon), which can occur during or months after treatment, and the exacerbation of muscle weakness in patients with Myasthenia Gravis.

Another critical safety concern is peripheral neuropathy, which involves pain, burning, tingling, numbness, and/or weakness. These nerve damage symptoms can be rapid in onset, disabling, and potentially irreversible. Central Nervous System (CNS) effects, such as seizures, psychosis, anxiety, and confusion, may also occur, sometimes after the first dose.

Additionally, Norxacin is associated with a risk of QTc interval prolongation on the heart's electrical activity, which can lead to life-threatening heart rhythm abnormalities (Torsade de Pointes). Other serious reactions include severe allergic (hypersensitivity) reactions and Clostridioides difficile-associated diarrhea (CDAD).

Common Side Effects

More common, generally milder reactions can include nausea, diarrhea, stomach cramps, dizziness, and headache.

Population-Specific Safety Considerations

Use is contraindicated in patients with a known history of hypersensitivity to Norxacin or other quinolones, or a history of tendonitis/tendon rupture related to quinolone use. Caution is advised for the elderly and those with kidney impairment, as dosage adjustments may be necessary due to a prolonged half-life. Patients should avoid excessive sunlight or UV exposure due to the risk of photosensitivity.

If any signs of tendon pain, nerve symptoms (pain, tingling), or serious allergic reactions occur, the medication should be discontinued immediately.

Overdose and Emergency Response

The official prescribing information for Norxacin (Norfloxacin) details specific clinical manifestations and mandated actions required in the event of an overdosage. The symptoms documented in regulatory sources include vomiting, diarrhoea, dizziness, tinnitus, and gastrointestinal haemorrhage. More severe neurological presentations, such as convulsions, are also recorded.


Severe Outcomes and Emergency Response

Overdose involving a potentially life-threatening amount requires immediate medical attention. This urgent response is necessary because significant poisoning may lead to severe systemic outcomes, notably acute renal failure and liver damage. In such cases, the regulator-mandated emergency procedures include measures for gastric decontamination, such as gastric lavage or inducing vomiting. Since no specific antidote is known, patient management is focused on providing symptomatic and supportive treatment.


Observation and Procedural Notes

Following the acute event, the patient must be carefully observed in a clinical setting. Regulatory documents note that the substance is not dialysable. Maintaining adequate hydration is required as a procedural step during management. No population-specific overdose severity considerations are explicitly documented in the acute overdose sections of the official labels.

Therapeutic Uses of Norxacin

What Norxacin Treats: Main Uses and Benefits

Norxacin (Norfloxacin) is generally used in areas where short-term symptom management is appropriate, and is relevant for conditions presenting with systemic or localized discomfort. The medicine is applied across domains where additional symptomatic support is needed. It generally provides support that helps ease the overall symptom load associated with these conditions.


Symptomatic Relief and Functional Support

Norxacin is commonly used when symptoms appear suddenly or intensify, creating noticeable interference with daily functioning. It may assist with short-term supportive relief, which helps patients cope more steadily during difficult, heightened periods of discomfort. This is often applied during phases of increased distress, where symptoms related to physical discomfort lead to functional strain.


Managing Episodic Discomfort

Relevant in conditions characterized by episodic or fluctuating symptom patterns, Norxacin helps address symptom clusters that may become intense or disruptive. The use of this medicine is aimed at offering symptomatic relief that may assist with maintaining functional stability when symptoms become more noticeable.


Quick Fact: Relief for Functional Strain Norxacin may assist with managing symptoms that create noticeable interference with daily functioning.

Regulatory References

  1. NIH LiverTox overview on Norfloxacin

Eligibility and Restrictions for Use

Regulatory documents establish strict population rules defining who can and cannot use Norxacin (Norfloxacin). Use is contraindicated for any individual with a history of hypersensitivity to Norfloxacin or any other quinolone antibiotic, or a history of tendon rupture associated with a prior quinolone [1.1, 2.3]. The medicine is also contraindicated in patients with a known history of myasthenia gravis [1.5].

Eligibility by Population Status

Category Regulatory Status
Pediatric Patients (Under 18) Contraindicated/Safety Not Established [1.6, 2.2]
Pregnancy Contraindicated/Not Recommended [1.1, 2.3]
Lactation Not Recommended/Must Discontinue Breastfeeding [1.1, 2.3]

Eligibility is restricted in several adult populations [1.6]. Patients with impaired renal function (Creatinine clearance le 30 mL/min) require an alteration of dosage to avoid drug accumulation [2.4]. Caution is mandated for older adults (ge 60 years), transplant recipients, and those taking corticosteroids due to the increased risk of tendon issues [1.6]. Use also requires caution in individuals with known risk factors for QTc prolongation or a history of seizures or other central nervous system disorders [1.6].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Norxacin (Norfloxacin) primarily through two pharmacokinetic mechanisms and specific pharmacodynamic risks.


Pharmacokinetic Interactions

Norfloxacin is a documented inhibitor of the Cytochrome P450 1A2 (CYP1A2) enzyme. This inhibition reduces the clearance of co-administered drugs that are CYP1A2 substrates, potentially leading to increased plasma concentrations of substances like Theophylline and Caffeine. A second major pharmacokinetic interaction involves chelation in the gastrointestinal tract. Multivalent cation-containing products, such as antacids and iron/zinc supplements, significantly reduce Norxacin absorption.

Interaction Type Interacting Substance Categories
Reduced Absorption Multivalent Cation-Containing Products, Dairy Products
Reduced Clearance CYP1A2 Substrates (e.g., Theophylline, Caffeine)

Pharmacodynamic Risks and Restrictions

Co-administration with Tizanidine is contraindicated due to the risk of severely increased Tizanidine exposure. Pharmacodynamic cautions exist for drugs that increase specific risks. Concurrent use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the potential for CNS stimulation. Caution is also required when Norxacin is co-administered with drugs that prolong the QT interval due to the risk of additive cardiac effects. Furthermore, Norfloxacin may enhance the effect of oral anticoagulants like Warfarin, necessitating close monitoring.


Administration Timing Constraints

Official labels mandate strict timing separation: multivalent cation-containing agents must not be taken within two hours before or after Norxacin administration to mitigate reduced absorption.

Mechanism of Action

How Norxacin Works

Norxacin's mechanism of action, derived from Norfloxacin, is entirely focused on the deliberate destruction of susceptible bacterial cells, achieving a definitive bactericidal effect.


Dual-Enzyme Inhibition and Genetic Sabotage

The drug's core action is the inhibition of two vital bacterial enzymes: DNA gyrase and Topoisomerase IV. These targets are essential for managing the bacterial DNA structure and replication. By binding to the transient DNA-enzyme complex, Norxacin prevents the enzymes from completing the DNA repair cycle, leading to the rapid and irreversible accumulation of double-stranded DNA breaks within the bacterial genome. This molecular sabotage is the primary step that initiates the lethal process.


The Bactericidal Cascade and Cellular Collapse

The overwhelming genetic damage triggers an intensive bacterial stress response, leading to the uncontrolled generation of cytotoxic molecules, particularly Reactive Oxygen Species (ROS). This destructive cascade rapidly escalates the molecular assault into complete cessation of cellular functions. The resulting physiological consequence is the definitive bacterial cell death, which achieves the physical elimination of susceptible organisms rather than merely halting their growth.


️ Functional Constraints and Limitations of Efficacy

The successful execution of this mechanism is biologically constrained. The drug's action can be functionally weakened by bacterial resistance mechanisms, such as mutations in the target enzyme genes or the increased activity of efflux pumps that actively expel Norxacin from the bacterial cell. These constraints define the boundaries where the mechanism is less effective, leading to a reduced functional effect of the mechanism.

Dosage and Administration Information

Norxacin (Norfloxacin) is used primarily through the oral route via a 400 mg tablet for the management of susceptible systemic infections. The standard administration schedule mandates a dose of 400 mg twice daily (every 12 hours), ensuring a total daily dosage of 800 mg. The overall treatment duration is dependent on the condition, ranging from a single 800 mg dose for specific uncomplicated infections to a longer course, such as 28 days for chronic bacterial prostatitis. The protocol for uncomplicated cystitis often specifies a three-day duration.

Official use instructions specify timing requirements relative to ingestion. The tablet must be taken with a full glass of water, and administration must be separated from both food and dairy products, requiring the dose to be taken at least one hour before or two hours after a meal. This separation is also mandatory for products containing multivalent cations, such as iron, zinc, and antacids, which must not be taken within two hours of the dose.

The required dosage is modified for patients with specific health conditions. For individuals with severe renal impairment (creatinine clearance less than or equal to 30 mL/min/1.73 m^2), the standard dosing schedule is reduced to 400 mg once daily. Furthermore, the safety and efficacy of the medicine are not established for pediatric patients. The tablets are intended to be swallowed whole, and instructions regarding missed doses strictly prohibit doubling the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Norxacin

Research Evidence for Uncomplicated Urinary Tract Infections (UTI)

The evidence base for Norfloxacin in uncomplicated urinary tract infections includes Randomized Controlled Trials (RCTs). These studies evaluated the medicine against a placebo and against other tested antimicrobial agents, exploring patient-reported outcomes related to physical discomfort. The primary research examined the medicine in adult female outpatients presenting with conditions characterized by acute or disruptive episodes.

The findings describe patterns related to microbiological status, which measures the observed suppression or absence of the offending pathogen, as well as the measurement of overall symptom changes. A key limitation is that much of the core evidence used to define the initial evidence base is historical. The body of evidence remains limited in describing how current bacterial resistance to this class of antibiotics relates to reported outcomes.

Research Evidence for Evaluating Spontaneous Bacterial Peritonitis (SBP)

Norfloxacin was studied for continuous, long-term administration in a research context evaluating the reduction of the incidence of Spontaneous Bacterial Peritonitis (SBP), a serious complication often associated with liver cirrhosis and ascites. The research utilized long-term Randomized Controlled Trials (RCTs) and systematic reviews, including populations defined by specific risk factors.

Studies reported measurements of both the incidence rate of SBP recurrence and all-cause mortality. Outcomes related to all-cause mortality were monitored in varied research settings, and data show patterns related to the measured outcomes varying across different analyses. Evidence remains limited regarding the consistency of long-term mortality measurements, and subgroup findings are uncertain across all possible high-risk patient types.

Evidence Gaps, Inconsistency, and Uncertainty

The overall research landscape has several known limitations. The age of much of the primary evidence base means that current microbiological trends were not characterized in the original studies. A critical finding in the evidence landscape relates to the research context for Norfloxacin in complicated kidney infection (pyelonephritis). Despite being studied, the regulatory review of this specific infection context reported a determination that the evidence base was inadequate to support the indication. This highlights that data for certain groups in complex infectious conditions remains insufficient.

Key Studies & References

  1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury - Norfloxacin

Frequently Asked Questions (FAQ)

Common questions about Norxacin (FAQ)


Q: How quickly should I expect Norxacin to start working?

Regulatory documents indicate that the highest concentration of the active ingredient in the bloodstream is reached approximately one to two hours after the tablet is taken orally. This measurement describes when the medicine reaches its highest level in the body's circulation, though the time to feel an observable effect varies among individuals.


Q: How long does Norxacin stay in your system after stopping?

Pharmacokinetic data from official sources describes the elimination half-life of the active ingredient as typically three to four hours in a healthy person. The half-life is the time it takes for the concentration of the medicine in the bloodstream to be reduced by half. The medicine is primarily cleared from the body through a process called renal excretion (via the kidneys).


Q: Is it possible to have an allergic reaction to Norxacin?

Yes, regulatory documents warn that severe allergic (hypersensitivity) reactions, including anaphylaxis, have been reported with this drug. Official warnings describe severe allergic reactions, which can include symptoms such as hives, swelling, or trouble breathing.


Q: Is Norxacin safe for people with liver problems?

Official information indicates that serious liver problems, such as hepatotoxicity (liver damage) and jaundice, have been reported with the use of this medication. For individuals with pre-existing liver disease, official information advises careful consideration due to these reports.


Q: What kind of studies have been done on Norxacin?

The research evidence base for Norxacin includes Randomized Controlled Trials (RCTs). These studies are used to evaluate the drug's effectiveness for conditions like urinary tract infections and to study its long-term use in reducing the risk of spontaneous bacterial peritonitis (SBP).


Q: What happens if I forget to take a dose of Norxacin?

Instructions found in the official product information strictly state that a person must not double the dose to make up for a dose that was forgotten.


Q: What is the difference between the active ingredient and the name Norxacin?

The active ingredient and generic name is Norfloxacin, which is the chemical substance responsible for the drug’s effects. Norxacin is the commercial brand name used for the pharmaceutical product containing Norfloxacin, as identified in official product labeling.


Q: Can Norxacin be crushed or split?

The official administration instructions state that Norxacin tablets are intended to be swallowed whole with a full glass of water. There are no instructions in the regulatory documents that authorize or recommend crushing or splitting the tablets.


Q: Does Norxacin affect the ability to drive or operate machinery?

Regulatory documents list side effects such as dizziness and drowsiness as potential reactions. These effects could potentially impair a person's functional ability to drive or safely operate machinery.


Q: Is there a special type of Norxacin for long-term use?

The active ingredient, Norfloxacin, is supplied in different forms depending on the area being treated. It is available as tablets for oral use, and as sterile aqueous solutions for topical use, such as for the eyes (ophthalmic) or ears (otic) applications.


Q: If I have a history of allergies, can I still take Norxacin?

Official labeling states the medicine is contraindicated (is not recommended for use) in individuals with a known history of hypersensitivity to Norfloxacin or any other drug belonging to the quinolone class of antibiotics.


Q: Why is Norxacin prescribed for conditions other than the primary one?

According to the official product information, the drug is indicated (approved) by regulatory agencies to treat several different types of susceptible bacterial infections. These indications may include complicated and uncomplicated urinary tract infections, as well as chronic bacterial prostatitis.


Q: Can Norxacin make you feel tired or drowsy?

Official reports of side effects include both drowsiness and weakness/fatigue as possible reactions to the medicine.


Q: Does Norxacin affect sleep patterns?

Yes, official adverse reaction reports list side effects that affect the Central Nervous System, including insomnia (trouble sleeping) and other sleep disturbances.


Q: Are there any long-term side effects associated with Norxacin use?

The medicine carries strong warnings about serious adverse reactions, such as tendon rupture and peripheral neuropathy (nerve damage). These serious effects can be disabling and are sometimes reported as potentially irreversible. Reports indicate they can occur during use or months after treatment has been completed.


Q: Is Norxacin known to cause weight gain or loss?

Weight changes are not commonly listed as general side effects. However, official reports note effects like changes in blood sugar, which may be associated with weight changes.


Q: Does Norxacin cause sun sensitivity?

The official warnings advise that the drug is associated with a risk of photosensitivity, which is a severe reaction to sunlight. Patients are strongly advised to avoid excessive sunlight or UV exposure while they are taking this medication.


Q: Why do people sometimes stop taking Norxacin prematurely?

Regulatory documents state that the medication is recommended to be discontinued immediately if a person experiences initial signs of certain serious reactions. These reactions include new or worsening signs of tendon pain, symptoms of nerve damage (like tingling or numbness), or any signs of a severe allergic reaction.


Q: Are there any mood changes associated with Norxacin?

Reported Central Nervous System effects from official sources include behavioral and mood changes. These can include anxiety, confusion, depression, and severe psychotic reactions.


Q: How does the body eliminate Norxacin?

Pharmacokinetic data shows that the active ingredient is eliminated from the body primarily through renal excretion (via the urine), and also through the bile and some metabolism. This process determines how long the medicine remains in the system.


Q: Is Norxacin a controlled substance?

According to official regulatory sources, the active ingredient, Norfloxacin, is not classified as a controlled substance under the federal Controlled Substances Act (CSA).

How should Norxacin be stored and disposed of?

How to Store and Dispose of Norxacin?

Norxacin (Norfloxacin) must be stored in specific environmental conditions to maintain stability and effectiveness.

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and do not freeze.
Protection Protect from light, heat, and moisture. Keep tablets in their closed or original container.
Child Safety Mandatory instruction to keep out of the reach and sight of children.
Disposal Do not dispose of via wastewater or household trash. Consult a pharmacist or healthcare professional for guidance on using an official drug take-back program for unused or expired medicine.

For Norfloxacin ophthalmic solution, regulatory guidance may require discarding the product 4 weeks after first opening.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Norxacin found in:

A-Z Index: